Premium
Effects of prebiotics on postprandial GLP‐1, GLP‐2 and glucose regulation in patients with type 2 diabetes: A randomised, double‐blind, placebo‐controlled crossover trial
Author(s) -
Birkeland Eline,
Gharagozlian Sedegheh,
Gulseth Hanne L.,
Birkeland Kåre I.,
Hartmann Bolette,
Holst Jens J.,
Holst René,
Aas AnneMarie
Publication year - 2021
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.14657
Subject(s) - postprandial , medicine , type 2 diabetes , crossover study , placebo , incretin , glucagon like peptide 1 , insulin , endocrinology , glycemic , population , diabetes mellitus , prebiotic , meal , food science , chemistry , alternative medicine , environmental health , pathology
Aims We aimed to investigate the effect of prebiotic inulin‐type fructans (ITF) versus a control supplement on postprandial levels of glucagon‐like peptide‐1 and ‐2 (GLP‐1 and ‐2), glucose and insulin in people with type 2 diabetes. Methods Adult men and women with type 2 diabetes were randomised in a double‐blind, placebo‐controlled crossover study. The study participants received 16 g/d ITF and 16 g/d control supplement (maltodextrin) for 6 weeks each in two phases separated by a 4‐week washout. A standardised mixed‐meal test was performed before and after each intake period. The primary end point was changes in the GLP‐1 response, and secondary end points were GLP‐2, glucose and insulin responses. Data were analysed using mixed‐model analysis. Results A total of 29 participants were included in the study. Differences between and within the two treatments in estimated area under the curves were not significant. Yet, the predicted means for meal‐induced GLP‐1 response in plasma showed a 4.8% decline after the prebiotic treatment and an 8.6% increase after the control treatment (difference in changes between the treatments, p < 0.001). Fasting or postprandial glucose, insulin or GLP‐2 levels were not changed. Conclusions Our findings do not support that ITF improve incretin responses or glucose regulations in this population. Clinicaltrials.gov (NCT02569684).